OncoMatch/Clinical Trials/NCT05179889
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Is NCT05179889 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including mFOLFIRINOX and mFOLFOX 6 for colon cancer stage iii.
Treatment: mFOLFIRINOX · mFOLFOX 6 — A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — curative radical resection (successful R0 resection) within 60 days before randomization
Curative radical resection (successful R0 resection) within 60 days before randomization
Lab requirements
Blood counts
ANC ≥ 2×10^6 cells/mL; hemoglobin ≥ 9.0 g/dL; platelets ≥ 100×10^6 cells/mL
Kidney function
serum creatinine ≤1.5 × ULN or creatinine clearance > 50 mL/min (Cockcroft-Gault formula)
Liver function
ALT/AST ≤2.5 × ULN; serum total bilirubin ≤ 1.5 ULN; alkaline phosphatase ≤ 2.5 × ULN
Adequate organ functions: ANC ≥ 2×10^6 cells/mL; Hemoglobin ≥ 9.0 g/dL; Platelets ≥ 100×10^6 cells/mL; ALT/AST ≤2.5 × ULN; serum total bilirubin ≤ 1.5 ULN; alkaline phosphatase ≤ 2.5 × ULN; serum creatinine ≤1.5 × ULN or creatinine clearance > 50 mL/min (Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify